Columbia Laboratories to Host 3rd Quarter 2001 Financial Results Conference Call.Business Editors/Health & Medical Writers NEW YORK--(BUSINESS WIRE)--Nov. 8, 2001 Columbia Laboratories, Inc. (AMEX AMEX See: American Stock Exchange :COB) announced today that it will release its 2001 third quarter financial results on Monday, November 12, 2001 after the market closes. The Company will host a conference call on Tuesday, November 13, 2001 at 9:00 a.m. EST EST electroshock therapy. EST abbr. electroshock therapy to review the financial results for the third quarter of 2001. Investors and other interested parties may access the call through Vcall at: http://www.vcall.com/NASApp/VCall/EventPage?ID=79524. To listen to the live call, please go to the "Investors" section of the web site at least fifteen minutes prior to register, download, and install any necessary audio software. If you are unable to participate, a replay will be available within 2 hours after the completion of the call by logging onto the aforementioned link. Columbia Laboratories, Inc. is a U.S.-based international pharmaceutical company dedicated to research and development of women's health Women's Health Definition Women's health is the effect of gender on disease and health that encompasses a broad range of biological and psychosocial issues. care and endocrinology products, including those intended to treat infertility, dysmenorrhea dysmenorrhea Pain or cramps before or during menstruation. In primary dysmenorrhea, caused by endocrine imbalances, severity varies widely. Irritability, fatigue, backache, or nausea may also occur. , endometriosis endometriosis (ĕn'dəmē'trē-ō`sĭs), a condition in which small pieces of the endometrium (the lining of the uterus) migrate to other places in the pelvic area. and hormonal deficiencies. Columbia is also developing hormonal products for men and a buccal buc·cal adj. 1. Of, relating to, adjacent to, or in the direction of the cheek. 2. Of or relating to the mouth cavity. buccal delivery system for peptides. Columbia's products primarily utilize the company's patented bioadhesive delivery technology. This press release contains statements that constitute forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Those statements include statements regarding the intent, belief or current expectations of the company and its management team. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements. Such risks and uncertainties include, among other things, timely and successful re-launch of Crinone back into the marketplace, timely and successful completion of clinical studies, competitive economic and regulatory factors in the pharmaceutical and health care industry, general economic conditions and other risks and uncertainties that may be detailed, from time-to-time, in Columbia's reports filed with the Securities and Exchange Commission. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion